Skip to main content
. 2019 Dec 27;38(10):1006–1018. doi: 10.1200/JCO.19.00895

FIG 1.

FIG 1.

(A) Schematic of 44 patients enrolled by diagnosis and CSF3R mutation status. Mut, CSF3R-T618I (n = 20), -T615A (n = 1), or -T640N (n = 1); WT, CSF3R–wild type; NR, nonresponder, 15 of 44 (34.1%) withdrew from study before the end of cycle 6; > C6, patients reached the end of cycle 6, 29 of 44 (65.9%). (B) Waterfall plot of absolute change of various hematologic parameters according to individual patients. Numbering of patients is arbitrarily based on the order presented in the heat map by mutation profile in Figure 2. The flat end of the line represents baseline value and the diamond-head end represents the end of cycle 6 value. Presented in this manner, both minimal and significant changes can be assessed on an individual basis. (†) Incidences of complete normalization of WBC, hemoglobin (Hgb) increases by > 2 g/dL, platelet (Plt) increases by > 30 × 109/L, and spleen volume reduction by ≥ 35%. aCML, atypical chronic myeloid leukemia; CNL, chronic neutrophilic leukemia.